Over the past year, CLGN insiders did not buy or sell the stock on the open market.
Beyond open-market trades, insiders at CollPlant Biotechnologies received 71.15K shares in stock awards in the last 12 months.
Per Business Quant data, CollPlant Biotechnologies insiders hold 72.28K shares in total based on their latest Form 4 filings.
CollPlant Biotechnologies insiders report no indirect holdings: all 72.28K shares are held directly.
Holdings in CollPlant Biotechnologies stock are reported by 2 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
CLGN's two largest insider shareholders, per their latest Form 4 filings, are Eran Rotem (Deputy CEO and CFO, 51.64K shares) and Bar Berta Abelis (VP Legal, 20.64K shares).
Of the shares held by CLGN insiders, 71.44% belong to Eran Rotem.
Institutional holders reported 13.70% of CollPlant Biotechnologies' outstanding shares for Q2 2026.
In the last 12 months, 2 Form 4 filings with transactions in CLGN stock came from 2 insiders.
The insider holdings and trades above for CollPlant Biotechnologies reflect Form 4 filings through September 8, 2026.
Form 4 Holdings
Insiders Holding CLGN
Insiders2
Shares held72.28K
Of outstanding5.92%
#
Insider
Position
Direct
Indirect
Total
Share of Insiders
Last Filed
1
Eran Rotem
Deputy Ceo And Cfo
51,637
0
51,637
71.4%
08 Sep, 2026
2
Bar Berta Abelis
Vp Legal
20,644
0
20,644
28.6%
08 Sep, 2026
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.